NAS:ORGS (USA) Also Trade In: Germany
Orgenesis Inc $ 6.36 0.03 (0.47%)
Warning! GuruFocus has detected 3 Severe warning signs with ORGS. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Orgenesis Inc () from 2010 to Jan 24 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Orgenesis stock (ORGS) PE ratio as of Jan 24 2021 is 2.31. More Details
Orgenesis PE Ratio (TTM) Historical Data
View and export this data going back to 2010. Start your Free Trial
Orgenesis PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:CERC NAS:EVLO AMEX:LCTX NAS:ABUS NAS:PIRS NAS:DYAI NAS:AVEO NAS:LOGC NAS:MBIO NAS:ENOB OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.